|Study Period:||2018 - 2026|
|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The canine atopic dermatitis market was valued at approximately USD 683.63 million in 2020. It is expected to witness a revenue of USD 1,107.86 million in 2026, with a CAGR of 8.46% over the forecast period (2021-2026).
The impact of COVID-19 on the canine atopic dermatitis market is expected to be significant. As per the data of the Centers for Disease Control and Prevention, cats, dogs, and a few other types of animals are at potential risk of acquiring this virus. Several studies are still ongoing concerning the connection between animals and human transmission of this virus. However, governments have been taking measures to mitigate the supply of medicines. For instance, the European Medicines Agency issued guidance for companies responsible for veterinary medicines, regarding the adaptations to the regulatory framework, primarily to address the challenges faced during the pandemic. IN July 2020, the Centers for Disease Control and Prevention recommended certain guidelines to the veterinary professionals for the treatment of companion animals during the COVID-19 pandemic. Additionally, as per the research article published in Humanities and Social Sciences Communications, 2020, the total number of online searches on the Yad4 website was 221,959 in April 2020 compared to 72,703 in April 2019. The study revealed the growing rate of dog adoption during the pandemic. Therefore, owing to such factors, the canine atopic dermatitis market is expected to be impacted during the pandemic.
Environmental factors are responsible for many allergies and diseases, which is expected to drive market growth. Increasing R&D activities are also expected to drive the market. For instance, in January 2020, Boragen partnered with one of the global leading animal health companies, exclusively for the R&D activity related to the development of new treatment of canine atopic dermatitis. Also, as per the research article published in Veterinary Medicine and Science, 2020, Luteolin was evaluated to study the antioxidant effect in the treatment of canine atopic dermatitis. The results revealed that Luteolin was able to drastically minimize the levels of IL‐33, IL 1β, IL‐6, and IL‐8 and suggested that Luteolin is a promising agent in pharmacological treatment for canine atopic dermatitis. Hence, such factors are expected to boost the canine atopic dermatitis market during the forecast period.
Scope of the Report
Canine atopic dermatitis is the chronic inflammation on the skin of dogs, often caused by allergens such as pollens, flea or other insect bites, and food ingredients. The canine atopic dermatitis market is segmented by treatment type (glucocorticoids, immuno-suppressants, monoclonal antibody, and other treatment types), route of administration (topical, oral, and injectable), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value in USD million for the above-mentioned segments.
|By Treatment Type|
|Other Treatment Types|
|By Route of Administration|
Key Market Trends
The Monoclonal Antibody Segment is Expected to Exhibit Significant Market Growth Over the Forecast Period
The monoclonal antibodies segment is expected to exhibit a thriving market growth over the forecast period. The major attributable factors are the rising awareness of biotherapeutics and the increasing product approvals.
Lokivetmab is a caninized anti–interleukin-31 (IL-31) mAb developed and licensed by Zoetis. It works by neutralizing soluble IL-31 released primarily by lymphocytes. Lokivetmab is effective against atopic dermatitis and allergic dermatitis in dogs. Furthermore, in 2019, Kindred Biosciences developed a monoclonal antibody, Interleukin-31, for the treatment of canine atopic dermatitis. It completed its pilot study and showed a significant outcome. Hence, advancements in products are expected to positively influence the market.
As per the research article published in the Asian Journal of Epidemiology, 2020, the development of monoclonal antibodies is expected to show similar growth in veterinary medicine that aids in providing promising alternative strategies to overcome the obstacles of drug resistance, adverse effects of drugs, drug residue, and other complications associated with the traditional veterinary drugs. Thus, owing to the aforementioned factors, therapeutic monoclonal antibodies are gaining importance in the treatment of allergic conditions in dogs, which may boost market growth over the forecast period.
To understand key trends, Download Sample Report
North America is Expected to Hold a Significant Share in the Market During the Forecast Period
North America is expected to be a dominant region for the canine atopic dermatitis market, owing to increased spending in R&D activities and the high concentration of key players in the market, along with the high rate of households with dog ownership in the region. According to the Animal Health Institute, the US animal health industry serves around 640 million food animals and 383 million companion animals.
As per the Canadian Animal Health Institute (CAHI), in 2018, there were nearly 8.2 million dogs in Canada. Over a decade, dog ownership has increased significantly in the country. As per the American Pet Products Association, nearly 63.4 million households in the United States owned a dog in 2020. Additionally, dogs occupy 63.4% of the pet share in the United States and owners spend an average of around USD 1,380 on pet dogs’ basic expenses. Thus, high dog ownership in the region is expected to drive market growth.
Also, the new product approvals and strategic alliances by key players are expected to boost the studied market. For instance, in October 2020, Elanco signed an agreement to acquire Bayer’s Animal Health business in a transaction valued at USD 7.6 billion. Thus, owing to the aforementioned factors, the North American canine atopic dermatitis market is expected to register significant growth over the forecast period.
To understand geography trends, Download Sample Report
The canine atopic dermatitis market is moderately competitive in nature, with few players dominating the market. Some of the key players that are expected to dominate the canine atopic dermatitis market are Zoetis, Elanco, Virbac, Toray Industries Inc., Dechra Veterinary Products, Kindred Biosciences Inc., and Ceva. The companies adopt various strategies, such as mergers and acquisitions, partnerships, and collaborations, along with the new product launches and research activities, to explore their positions in the market.
In October 2020, Virbac received US FDA approval for its CYCLAVANCE (cyclosporine oral solution) USP MODIFIED to control atopic dermatitis in dogs weighing at least 4 lbs (1.8 kg).
In September 2020, Zoetis received a variation to the terms of the marketing authorization for the veterinary medicinal product, Cytopoint, by the Committee for Medicinal Products for Veterinary Use (CVMP), in which the variation concerns adding a new therapeutic indication for the treatment of pruritus associated with allergic dermatitis in dogs.
Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Pollution Related to Allergens
4.2.2 Increasing dog ownership
4.3 Market Restraints
4.3.1 Usage of Off-label Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Treatment Type
5.1.3 Monoclonal Antibody
5.1.4 Other Treatment Types
5.2 By Route of Administration
5.3.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
5.3.4 Middle East and Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle East and Africa
5.3.5 South America
184.108.40.206 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.4 Toray Industries Inc.
6.1.5 Kindred Biosciences Inc.
6.1.8 Dechra Veterinary Products
6.1.9 Vetoquinol UK Ltd
6.1.11 Phibro Animal Health Corporation
6.1.12 Bioiberica S.A.U.
6.1.13 Bimeda, Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global Canine Atopic Dermatitis Market market is studied from 2018 - 2026.
What is the growth rate of Global Canine Atopic Dermatitis Market?
The Global Canine Atopic Dermatitis Market is growing at a CAGR of 8.46% over the next 5 years.
What is Global Canine Atopic Dermatitis Market size in 2018?
The Global Canine Atopic Dermatitis Market is valued at 683 Million USD in 2018.
What is Global Canine Atopic Dermatitis Market size in 2026?
The Global Canine Atopic Dermatitis Market is valued at 1107 Million USD in 2026.
Which region has highest growth rate in Global Canine Atopic Dermatitis Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Canine Atopic Dermatitis Market?
North America holds highest share in 2020.
Who are the key players in Global Canine Atopic Dermatitis Market?
Zoetis, Virbac, Toray Industries Inc., Elanco, Dechra Pharmaceuticals PLC are the major companies operating in Global Canine Atopic Dermatitis Market.